Loading…
Based on limited metadata from the FDA Warning Letter issued to lekapharma.com on August 31, 2020, the letter concerns drug products and their manufacture or marketing. Without access to the full letter text or detailed subject information, the specific nature of the violations cannot be determined from the metadata alone. The warning was issued under FDA's drug regulatory authority, indicating the agency identified compliance concerns significant enough to warrant formal notice. Additional documentation would be needed to identify the particular manufacturing, labeling, or marketing violations cited.